AstraZeneca PLC's strategy of offloading mature brands to boost reinvestment into its pipeline is picking up speed again with the sale of commercial rights to cancer drugs Arimidex and Casodex in a number of European, African and other countries to France's Juvisé Pharmaceuticals.
The UK major is getting $181m up front and is eligible to receive future sales-contingent payments of up to $17m for the two off-patent drugs